PURPOSE: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. EXPERIMENTAL DESIGN: Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. RESULTS: High expression of the Bad protein [hazard ratio (HR), 0.64; 95% confidence interval (95% CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95% CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95% CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). CONCLUSION: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancer patients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.
PURPOSE: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. EXPERIMENTAL DESIGN:Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. RESULTS: High expression of the Bad protein [hazard ratio (HR), 0.64; 95% confidence interval (95% CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95% CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95% CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). CONCLUSION: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancerpatients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.
Authors: Michael J O'Connell; Daniel J Sargent; Harold E Windschitl; Lois Shepherd; Michelle R Mahoney; James E Krook; Sandra Rayson; Roscoe F Morton; Kendrith M Rowland; John W Kugler Journal: Clin Colorectal Cancer Date: 2006-07 Impact factor: 4.481
Authors: Simon N Willis; Jamie I Fletcher; Thomas Kaufmann; Mark F van Delft; Lin Chen; Peter E Czabotar; Helen Ierino; Erinna F Lee; W Douglas Fairlie; Philippe Bouillet; Andreas Strasser; Ruth M Kluck; Jerry M Adams; David C S Huang Journal: Science Date: 2007-02-09 Impact factor: 47.728
Authors: Frank A Sinicrope; Rafaela L Rego; Kevin C Halling; Nathan Foster; Daniel J Sargent; Betsy La Plant; Amy J French; John A Laurie; Richard M Goldberg; Stephen N Thibodeau; Thomas E Witzig Journal: Gastroenterology Date: 2006-09 Impact factor: 22.682
Authors: Sandra S Zinkel; Kristen E Hurov; Christy Ong; Farvardean M Abtahi; Atan Gross; Stanley J Korsmeyer Journal: Cell Date: 2005-08-26 Impact factor: 41.582
Authors: Frank A Sinicrope; Rafaela L Rego; Kevin C Halling; Nathan R Foster; Daniel J Sargent; Betsy La Plant; Amy J French; Carmen J Allegra; John A Laurie; Richard M Goldberg; Thomas E Witzig; Stephen N Thibodeau Journal: Clin Cancer Res Date: 2006-05-01 Impact factor: 12.531
Authors: Suzanne Trudel; Zhi Hua Li; Jennifer Rauw; Rodger E Tiedemann; Xiao Yan Wen; A Keith Stewart Journal: Blood Date: 2007-03-01 Impact factor: 22.113
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Yi Huang; Dan Liu; Bojiang Chen; Jing Zeng; Lei Wang; Shangfu Zhang; Xianming Mo; Weimin Li Journal: Med Oncol Date: 2011-09-15 Impact factor: 3.064
Authors: Hye Sook Chon; Douglas C Marchion; Yin Xiong; Ning Chen; Elona Bicaku; Xiaomang Ba Stickles; Nadim Bou Zgheib; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Johnathan M Lancaster Journal: Gynecol Oncol Date: 2011-10-26 Impact factor: 5.482
Authors: Li Jiang; Man Luo; Dan Liu; Bojiang Chen; Wen Zhang; Lin Mai; Jing Zeng; Na Huang; Yi Huang; Xianming Mo; Weimin Li Journal: Cancer Cell Int Date: 2013-06-01 Impact factor: 5.722